{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:19:37Z","timestamp":1789154377792,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":72,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100506","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:22:27Z","timestamp":1741998147000},"page":"100506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia\/lymphoblastic lymphoma treatment: A case report and literature review"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9714-6476","authenticated-orcid":false,"given":"Alaa Eldein","family":"Yahia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Motabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Alsakkaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila M.","family":"Alsuhaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Albtoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Khaled","family":"AlBathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Alrajhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2025.100506_bib0001","series-title":"Ash-sap: American society of Hematology Self-Assessment Program","author":"Cuker","year":"2019"},{"issue":"24","key":"10.1016\/j.lrr.2025.100506_bib0002","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features,immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2025.100506_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25896","article-title":"Outcome of adults with relapsed\/refractory t-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"95","author":"Samra","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"20","key":"10.1016\/j.lrr.2025.100506_bib0016","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2022017341","article-title":"Mechanisms of resistance to venetoclax","volume":"140","author":"Condoluci","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2025.100506_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.lrr.2025.100506_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00172","article-title":"Venetoclax and bortezomib in relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia","author":"Starza","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"8","key":"10.1016\/j.lrr.2025.100506_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"issue":"12","key":"10.1016\/j.lrr.2025.100506_bib0012","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100506_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/524308","article-title":"The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias","volume":"2012","author":"Tzifi","year":"2012","journal-title":"Adv. Hematol."},{"issue":"4","key":"10.1016\/j.lrr.2025.100506_bib0008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ccr.2010.09.009","article-title":"T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation","volume":"18","author":"Feng","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lrr.2025.100506_bib0009","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lrr.2025.100506_bib0024","series-title":"Veneotoclax Plus Decitabine in the Treatment of MRD-persistent and Relapsed\/Refractory T-cell Acute Lymphoblastic Leukemia","first-page":"EP427","author":"Parovichnikova","year":"2020"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2025.100506_bib0025","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1182\/blood-2024-204740","article-title":"Combination of venetoclax and Daratumumab plus CAG regimen in adult T-cell acute lymphoblastic leukemia with persistent positive minimal residual disease","volume":"144","author":"Peng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100506_bib0026","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2019-129988","article-title":"A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed\/refractory acute lymphoblastic leukemia","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2025.100506_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with Venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2025.100506_bib0006","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1182\/blood-2018-99-113464","article-title":"Venetoclax and Navitoclax in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"132","author":"Alexander","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100506_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.lrr.2025.100506_bib0022","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.lrr.2025.100506_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.lrr.2025.100506_bib0013","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.lrr.2025.100506_bib0018","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood.V126.23.4910.4910","article-title":"Clofarabine based chemotherapy in adult relapsed\/refractory acute leukemia\/lymphoma: a single institution","volume":"126","author":"Alkhateeb","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100506_bib0027","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J. Haematol."},{"issue":"5","key":"10.1016\/j.lrr.2025.100506_bib0014","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.3390\/ijms24055004","article-title":"Venetoclax-resistant T-all cells display distinct cancer stem cell signatures and enrichment of cytokine signaling","volume":"24","author":"Shah","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lrr.2025.100506_bib0020","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","author":"Issa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lrr.2025.100506_bib0021","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016503","article-title":"How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults","author":"Si Lim","year":"2023","journal-title":"Blood"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:15:10Z","timestamp":1750180510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":25,"alternative-id":["S2213048925000081"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100506","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia\/lymphoblastic lymphoma treatment: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100506"}}